Oxaplain 50 Injection contains Oxaliplatin 50mg, a platinum-based chemotherapy agent indicated for the treatment of colorectal cancer, gastric cancer, and other solid tumors. It helps inhibit tumor growth, prevent metastasis, and improve clinical outcomes in cancer patients.
Oxaliplatin works by forming DNA cross-links in rapidly dividing cancer cells, disrupting replication and transcription, and inducing apoptosis. Its intravenous injection allows precise dosing and effective systemic delivery in oncology settings.
For distributors and healthcare suppliers, Oxaplain 50 Injection is a high-demand anticancer therapy product, widely used in hospitals, oncology centers, and chemotherapy clinics. The ongoing need for colorectal and solid tumor treatment ensures steady demand year-round.
Adding Oxaplain 50 Injection to your oncology therapy segment creates strong opportunities in hospitals, cancer care centers, export markets, and third-party manufacturing. Its proven efficacy, platinum-based formulation, and prescriber trust make it a valuable addition to pharmaceutical distribution portfolios.